280 reports of this reaction
2.6% of all CALCIUM CARBONATE, MAGNESIUM HYDROXIDE reports
#8 most reported adverse reaction
NEPHROGENIC ANAEMIA is the #8 most commonly reported adverse reaction for CALCIUM CARBONATE, MAGNESIUM HYDROXIDE, manufactured by THE PROCTER & GAMBLE MANUFACTURING COMPANY. There are 280 FDA adverse event reports linking CALCIUM CARBONATE, MAGNESIUM HYDROXIDE to NEPHROGENIC ANAEMIA. This represents approximately 2.6% of all 10,871 adverse event reports for this drug.
Patients taking CALCIUM CARBONATE, MAGNESIUM HYDROXIDE who experience nephrogenic anaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEPHROGENIC ANAEMIA is a less commonly reported adverse event for CALCIUM CARBONATE, MAGNESIUM HYDROXIDE, but still significant enough to appear in the safety profile.
In addition to nephrogenic anaemia, the following adverse reactions have been reported for CALCIUM CARBONATE, MAGNESIUM HYDROXIDE:
The following drugs have also been linked to nephrogenic anaemia in FDA adverse event reports:
NEPHROGENIC ANAEMIA has been reported as an adverse event in 280 FDA reports for CALCIUM CARBONATE, MAGNESIUM HYDROXIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEPHROGENIC ANAEMIA accounts for approximately 2.6% of all adverse event reports for CALCIUM CARBONATE, MAGNESIUM HYDROXIDE, making it a notable side effect.
If you experience nephrogenic anaemia while taking CALCIUM CARBONATE, MAGNESIUM HYDROXIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.